A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Clinical trial NCT07213674 · RECRUITING

Trial details

NCT number: NCT07213674
Sponsor: Amgen
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Castration-resistant Prostate Cancer

Start date: 2025-11-28
Primary completion: 2030-01-07
Enrollment: 750

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.